ArticleThe Journal of clinical investigation1996
Dermal injection of immunocytes induces psoriasis.
Article in The Journal of clinical investigation, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 436 citations in OpenAlex.
- Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris.Proceedings of the National Academy of Sciences of the United States of America · 2005Trial
- A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis.Annals of the rheumatic diseases · 2004Trial
- Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions.The Journal of clinical investigation · 1999Trial
- Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis.The Journal of clinical investigation · 1999Trial
- IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.The Journal of clinical investigation · 1998Trial
- Article
- Comparative analysis of cutaneous features of psoriasis in acute and chronic imiquimod-induced mouse models.Scientific reports · 2025Article
- Antiproliferative and Anti-Inflammatory Effects of the Polyphenols Phloretin and Balsacone C in a Coculture of T Cells and Psoriatic Keratinocytes.International journal of molecular sciences · 2024Article
- An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis.Current drug targets · 2024Review
- Effect of Systemic Administration of CD4Comparative medicine · 2023Article
- Blank Spots in the Map of Human Skin: The Challenge for Xenotransplantation.International journal of molecular sciences · 2023Review
- Article
- Mouse Models of Psoriasis: A Comprehensive Review.The Journal of investigative dermatology · 2022Review
- Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields.Frontiers in cellular and infection microbiology · 2021Review
- Role of Innate Immune Cells in Psoriasis.International journal of molecular sciences · 2020Review
- Psoriasis and Treatment: Past, Present and Future Aspects.Acta dermato-venereologica · 2020Review
- Review
- Therapeutic Effects of Synthetic Antimicrobial Peptides, TRAIL and NRP1 Blocking Peptides in Psoriatic Keratinocytes.Chonnam medical journal · 2019Review
- Infiltration of T Cells into a Three-Dimensional Psoriatic Skin Model Mimics Pathological Key Features.International journal of molecular sciences · 2019Article
- Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders.Frontiers in immunology · 2019Review
30 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Establishing direct and causal relationships among the confederacy of activated cell types present in psoriasis has been hampered by lack of an animal model. Within psoriatic plaques there are hyperplastic keratinocytes, infiltrating immunocytes, and activated endothelial cells. The purpose of this study was to determine if psoriasis is primarily a disorder of keratinocytes or the immune system. Using a newly developed experimental system in which full-thickness human skin is orthotopically transferred onto severe combined immunodeficient mice, autologous immunocytes were injected into dermis, and the resultant phenotype characterized by clinical, histologic, and immunophenotypic analyses. Engraftment of samples included both uninvolved/ symptomless (PN) skin removed from patients with psoriasis elsewhere, or from healthy individuals with no skin disease (NN skin). In 10 different experiments involving 6 different psoriasis patients, every PN skin was converted to a full-fledged psoriatic plaque skin by injection of autologous blood-derived immunocytes. In all but one psoriatic patient, the immunocytes required preactivation with IL-2 and superantigens to convert PN skin into psoriatic plaque skin. In every case, resultant plaques were characterized by visible presence of flaking and thickened skin, loss of the granular cell layer, prominent elongation of rete pegs with a dermal angiogenic tissue reaction, and infiltration within the epidermis by T cells. Lesional skin displayed 20 different antigenic determinants of the psoriatic phenotype. None of the four NN skin samples injected with autologous immunocytes converted to psoriatic plaques. We conclude that psoriasis is caused primarily by the ability of pathogenetic blood-derived immunocytes to induce secondary activation and disordered growth of endogenous cutaneous cells including keratinocytes and vascular endothelium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.